- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03203889
Testing Effectiveness of the Community Reinforcement Approach and Family Training (CRAFT) With American Indians (CRAFT-AI)
Randomized Controlled Trial of CRAFT With American Indians
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment research with AI/AN is in its infancy. One route to address the substantial substance use related health disparities is to employ evidence-based treatments (EBTs) with AI/AN. EBTs are rarely tested with sufficiently large samples of racial ethnic groups, so outcomes are often unknown. Recently, an R01 DA021672 adapted two EBTs for substance use disorders (SUDs) (motivational interviewing and community reinforcement approach - MICRA) and conducted a randomized controlled trial (RCT) to MICRA to treatment as usual with the same AI community as involved in this proposal. The present study seeks to expand on that R01, which culturally tailored CRA for people with SUDs, but now turn our focus to working with families and concerned significant others (CSOs) who want to help engage their loved one with an addiction (identified person; IP) into treatment. The intervention, Community Reinforcement and Family Training (CRAFT), is built on reinforcement principles. CRAFT teaches CSOs to take better care of themselves, to cease any behaviors that are not working to address the IP's substance use, and to consistently reward the IP for any sober and treatment engagement behavior. Importantly, CRAFT has been shown to increase IP entry into treatment, which would address: (1) the high rates of SUDs and related problems among AI/AN, (2) low rates of AI/AN self-referrals to treatment, and (3) higher rates of AI entering treatment due to court mandates. The present study aims to conduct an RCT to compare an AI culturally adapted version of CRAFT (CRAFT-AI; n=20) to Twelve-step facilitation for CSO's (TSF-CSO) using principles and groups of Nar/Al-Anon (n=20) to examine acceptability of a culturally tailored EBT and estimate effect sizes for IP treatment entry and for CSO functioning pre to post intervention. Notably, this will be the first examination of potential mediators and moderators of CRAFT-AI including variables such as: demographic variables, severity of SUD, self-efficacy, and cultural risk and protective factors. Finally, we will examine the appropriateness of broadening the dependent variable of IPs entering formal treatment to include AI traditional healing. The methodology of this grant using a partnership between academic and tribal researchers is well-poised to contribute to nascent AI/AN SUD treatment research to impact the substantial health disparities AI/ANs and other indigenous populations endure. Positive study results will facilitate future cultural adaptation research and dissemination and diffusion of EBTs to interested AI/AN tribes and other culturally diverse populations.
Quality Assurance 1. For quality assurance of data collection, Roberta Chavez, who has over 25 years of experience working on clinical trials at University of New Mexico (UNM)/Center on Alcoholism, Substance Abuse, and Addiction (CASAA), will train the research assistant and conduct data quality assurance checks monthly. Data entry will be conducted with two passes.
For the intervention, all counselors will receive expert training in either CRAFT-AI or TSF-CSO. All counselors will be certified in CRAFT-AI or demonstrate proficiency in TSF-CSO prior to the RCT using a CRAFT coding manual and TSF-CSO coding forms. All counseling sessions will be digitally recorded and coded for fidelity to the treatment modalities. When counselors do not pass a CRAFT module or TSF-CSO component, they will receive individualized training and remediation to meet fidelity requirements.
Transmission
a. All data will be collected using pre-specified measures, instruments, and qualitative questions. b. Entry of data will occur within 30 days after it is collected. Second pass within 60 days. c. Statistician, Katie Witkiewitz, will conduct analyses to insure data fidelity upon completion of data entry and reconciliation of any discrepancies.
Regulatory Issues 1. Reporting mechanisms of adverse events (AEs) and serious adverse events (SAEs) to Institutional Review Board (IRB) and National Institute on Drug Abuse (NIDA). The PI will report any SAE, whether or not related to study intervention to the UNM IRB, NIDA and the Zuni Tribal Council within 48 hours of the principal investigator's (PI's) notification of the SAE. Outcomes of SAEs will be reported to NIDA and the Zuni Tribal Council and UNM IRB as they become known. A summary of the SAEs that occurred during the previous year will be included in the annual progress report to NIDA, which will also be sent to the Zuni Tribal Council.
2. Reporting mechanisms of IRB actions to NIDA The PI will be responsible to report any IRB actions to NIDA.
3. Trial Stopping Rules In the event that those participants in the intervention arm receiving CRAFT-AI counseling experience a significantly higher rate of SAE's that are probably study related than those participants in TSF-CSO arm of the study, then the trial will be stopped.
Potential risks and benefits for participants The primary risks involved in this research project are: a) loss of confidentiality, b) discomfort talking about problems caused by loved one with a substance use problems, c) potential disclosure of own substance use problems, and c) potential for conflict between the subject and loved one. Steps have been taken to minimize the likelihood of these risks and to ameliorate them if they are present. Past studies have assessed for level of conflict and instituted safety plans in case domestic violence should be imminent or occur.
Participants may potentially benefit from receiving the CRAFT-AI or TSF-CSO interventions in terms of improved psychological functioning such as decreased anxiety and depression. In addition, their loved one may enter treatment.
Trial Efficacy Plans for Interim Analysis of Efficacy Data: We have no plans for interim analyses.
Data analysis plan Analysis Plan. Data Integrity Preliminary Analyses: First we will compare demographics and primary study measures at baseline between randomized treatment groups, using ANOVA for continuous variables (or Kruskal-Wallis if parametric assumptions are violated) and using χ2 tests for categorical variables. Subsequent analyses will adjust for significant baseline differences among the randomized groups. Additionally, the data will be examined for both missing cases and outlier scores on measures. Variable distributions will be checked for normality and if necessary, transformations will be performed to normalize the distributions.
Statistical Analysis Plan Aim #1 Analyses for Adaptations: We will use a blend of CSP and the ADAPT-ITT procedures to adapt CRAFT in partnership with this tribal community. Digital recordings from the four focus groups will be transcribed and reviewed for themes and important areas for cultural adaptations using NVivo software.
Aim #2: Analyses for pilot feasibility RCT (N=8) 3 month follow-up. The primary outcome of IP treatment/healing engagement will be examined using Hedges's g effect sizes to correct for small sample size bias with 95% confidence intervals of the effect sizes.
Aim #2a RCT (N=40): To estimate the effect of CRAFT-AI vs. TSF-CSO on IP treatment/healing entry (primary outcome) from intake to 3- and 6-month follow-ups. The primary outcomes of IP treatment/healing entry, and CSO functioning will be examined using an intent-to-treat analysis with a generalized linear mixed effects model with fixed effects of treatment and random effects of time. The model for IP engagement will be estimated using the binomial distribution and a logit link function. Additional analyses of CSO treatment sessions attended will be examined using a negative binomial hurdle model with a log link function, which will allow us to simultaneously test the effect of treatment on engagement (yes vs no) outcome and the count of sessions attended for CSOs with or without IP treatment entry. Demographic, substance use, and psychological variables for which the randomized groups differed significantly at baseline will be included as covariates in all models. In addition, attendance at other mutual help groups such as Nar/Al-Anon will be assessed and used as a covariate as necessary, especially for the CRAFT-AI CSOs. Models will be estimated using an intent-to-treat approach that analyzes data from all randomized participants. We will use maximum likelihood estimation for all analyses, which provides the variance-covariance matrix for all available data. While attrition in the previous RCT was less than 7% at 12 months, attrition analyses will determine whether there are any differences in study variables between those with missing and complete data. Study variables associated with missing data will be covaried in all analyses.
Statistical power for Aim #2a: The primary hypothesis is that participation in CRAFT-AI will predict greater engagement of IPs in treatment/healing, as compared to those assigned to TSF-CSO. Effect size estimates were drawn from a recent meta-analysis of CRAFT. Results from the meta-analysis indicated that IP engagement rate following CRAFT was on average 67%, while engagement IP rate following TSF-CSO was on average 18%, which results in an overall effect size odds ratio of 9.25. Given this effect size for odds of IP engagement between groups with α =.05 we will have 89% power with 18 subjects per condition (n=36) to detect the main effect of treatment. Assuming 10% dropout, we propose to recruit 20 subjects per condition (n=40) to assure a final sample size of 36.
Analyses for Aim #2b: To estimate the effect of CRAFT-AI and TSF-CSO on CSO functioning and relationship functioning (secondary outcomes) from intake to 3- and 6-month follow-ups. The secondary outcomes of CSO functioning and relationship functioning will be examined using latent growth curve modeling. We hypothesize that the slope of CSO functioning and relationship functioning will indicate that participants in both CRAFT-AI and TSF-CSO will show significant decreases in depression and anxiety and significant improvement in relationship functioning regardless of whether their IP enters treatment or healing ceremony.
Statistical power for Aim #2b: A Monte Carlo simulation study was conducted to determine power for the latent growth curve models. The population parameter values for data generation and coverage were taken from the parameter estimates of an analysis of prior alcohol treatment outcome studies. We are primarily interested in testing the hypothesis that the slope would be significantly greater than zero. Based on a sample size of 40 across both conditions, we will have power greater than .80 (α<.05) to detect a slope that is statistically different from zero.
Analyses for Aim #2c: While underpowered to identify all but large mediation effects, we plan to obtain estimates of effect sizes for future studies that will examine possible mechanism of change for CRAFT-AI and potential treatment moderators. Effect sizes for possible mechanisms of change will be derived from mediation models estimated using the product of coefficients method. Given that the distribution of the product of coefficients can be non-normal we will use bootstrapping to obtain 95% confidence intervals of the mediated effect. We will have power greater than .80 to detect large mediating effects with a final sample size of 36. Effect sizes for potential treatment moderators will be derived by including interaction terms (treatment x moderator) in the Aim 2a and Aim 2b analyses.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Mexico
-
Zuni, New Mexico, United States, 87327
- Zuni Recovery Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- are at least 18 years of age;
- are a member of this AI tribe and living within 60 mile radius of the research or treatment site (i.e., the reservation);
- are able to converse fluently in English (RA will read questions if English literacy is poor and may speak in their Native language with Native speakers);
- are concerned about an AI with an SUD (IP) who is an intimate partner, relative (sanguine or not), or close friend;
- have face-to-face contact with the IP at least 40% of the past 90 days, excluding any time in detention, with no planned change such as separation or moving out;
- describe the IP behavior as consistent with Diagnostic and Statistical Manual of Mental Disorders SUD criteria 5th edition, DSM-5;
- are willing to participate in the research; and
- report that the IP refused to seek treatment and had not received any treatment (other than detoxification) or traditional healing for SUD problems in the past 90 days, nor was court mandated to treatment.
Exclusion Criteria:
- meets criteria for injectable drug SUD (but other SUD allowable)
- shows signs of unremitted psychosis, any serious psychiatric condition, or cognitive impairment that could interfere with the CSO's ability to understand and participate in treatment;
- intends to seek more than 6 hours of additional behavioral health treatment (not including substance abuse treatment) in the next 3 months;
- has an IP who has received a Johnson Institute Intervention within the prior 3 years; or
- reports severe domestic violence (including use of a weapon or injury requiring hospitalization) at the hand of the IP.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CRAFT-AI
Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided.
A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use.
The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities.
In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use.
The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
|
Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
Other Names:
|
|
Active Comparator: 12-step facilitation for loved ones
12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions.
There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease.
The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP.
The CSO works to decrease enabling behaviors.
Counselors will help the CSO to work the program of Nar/Al-Anon.
|
In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identified person with addiction's treatment entry or seeking traditional healing
Time Frame: 6 months post CSO baseline
|
attending one session of formal substance use disorder treatment or one AI traditional healing session within 6 months of the CSO's 1st counseling session
|
6 months post CSO baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relationship functioning
Time Frame: 6 months post CSO baseline
|
dyadic adjustment scale score
|
6 months post CSO baseline
|
|
Concerned significant other functioning
Time Frame: 6 months post CSO baseline
|
Beck Depression Inventory II
|
6 months post CSO baseline
|
|
Concerned Significant Other functioning II
Time Frame: 6 months post CSO baseline
|
State Trait Anxiety Inventory
|
6 months post CSO baseline
|
|
Concerned Significant Other functioning III
Time Frame: 6 months post CSO baseline
|
State Trait Anger Expression Inventory
|
6 months post CSO baseline
|
|
Concerned Significant Other functioning IV
Time Frame: 6 months post CSO baseline
|
SF-36
|
6 months post CSO baseline
|
|
Relationship Functioning II
Time Frame: 6 months post CSO baseline
|
Family Environment Scale
|
6 months post CSO baseline
|
|
Relationship Functioning III
Time Frame: 6 month post CSO baseline
|
IP Conflict Tactics Scale
|
6 month post CSO baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
effect sizes
Time Frame: 6 months post CSO baseline
|
effect size between intervention arms primary outcomes and secondary outcomes
|
6 months post CSO baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kamilla Venner, PhD, University of New Mexico
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 947549-9
- R34DA040064-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use Disorders
-
University of ArkansasNational Center for Advancing Translational Sciences (NCATS)RecruitingParenting | Substance Use Treatment | Perinatal Substance UseUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Substance Use Disorder (SUD)United States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorders | Nicotine Use DisorderUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Active, not recruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Substance Use DisordersUnited States
-
Spark Biomedical, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); Baylor College... and other collaboratorsRecruitingSubstance Use Disorders | Alcohol Use Disorder | Alcohol Abuse | Substance Use Disorders Alcohol Use Withdrawal StateUnited States
Clinical Trials on CRAFT-AI
-
Stanford UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Southern... and other collaboratorsRecruitingAlcohol Drinking | Alcohol Use Disorder | Alcohol Abuse | Military Family | Relations, InterpersonalUnited States
-
Mclean HospitalNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Tobacco Use | Bipolar Disorder | Cannabis | Substance Use | Substance Use Disorders | Psychosis | Alcohol Use Disorder | Mental Disorder | Cigarette Smoking | Nicotine Use Disorder | Family | Marijuana | AlcoholUnited States
-
Hadassah Medical OrganizationHebrew University of Jerusalem; Israel Cancer AssociationRecruitingBreast Cancer Survivor | Cancer Related Cognitive ImpairmentIsrael
-
VA Office of Research and DevelopmentMinneapolis Veterans Affairs Medical Center; Corporal Michael J. Crescenz VA...Active, not recruitingStress Disorders, Post-traumaticUnited States
-
Mclean HospitalNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Cannabis | Substance Use | Substance Use Disorders | Psychosis | Mental Disorder | Family | Marijuana | AlcoholUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknownRefractory SchizophreniaBrazil
-
IrisZorgTerminatedSubstance Use Disorder | Addiction | Alcohol Use Disorder | Substance- Related DisorderNetherlands
-
Case Western Reserve UniversityExpanding Horizons InitiativeRecruitingDepression | Anxiety | MoodUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); MaryhavenUnknownHeroin Dependence | Opiate Dependence | Substance DependenceUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedChronic Obstructive Pulmonary DiseaseBrazil